论文部分内容阅读
目的:探讨阿莫西林/克拉维酸钾片的药代动力学与药效学。方法:选取我院自2015年6月~2016年6月收集的健康志愿者18名作为本次研究对象,给予所有研究对象单次阿莫西林/克拉维酸钾片口服625mg,运用微生物法对其尿药浓度及血药浓度进行测定。结果:阿莫西林主要药动力学参数:Cmax为(7.68±0.66)mg/L,tmax为(1.48±0.62)h,t1/2β为(1.34±0.52)h,AUC0-∞为(19.87±1.68)mg·h/L,CL为(28.22±3.97)L/h,24h尿累积排泄率(62.84±21.2)%;T>MIC为4.8h,占给药间隔比例38~64%。结论:阿莫西林/克拉维酸钾片625mg,3次/d给药,能够有效治疗呼吸道感染常见致病菌,值得临床推广应用。
Objective: To investigate the pharmacokinetics and pharmacodynamics of amoxicillin / clavulanate tablets. METHODS: Eighteen healthy volunteers collected in our hospital from June 2015 to June 2016 were selected as the study subjects. All subjects were given orally 625 mg of amoxicillin / clavulanate tablets orally. Urine drug concentration and plasma concentration were determined. Results: The main pharmacokinetic parameters of amoxicillin were as follows: Cmax was (7.68 ± 0.66) mg / L, tmax was (1.48 ± 0.62) h, t1 / 2β was (1.34 ± 0.52) h, AUC0-∞ was (19.87 ± 1.68 ) (mg · h / L), CL (28.22 ± 3.97) L / h, 24h urinary cumulative excretion rate (62.84 ± 21.2)%; T> MIC was 4.8h, accounting for 38 ~ 64% of the interval between administrations. Conclusion: Amoxicillin / clavulanate tablets 625mg, 3 times / d administration, can effectively treat common pathogens of respiratory tract infection, worthy of clinical promotion and application.